Jianxin Superconducting Science and Technology Innovation Board's IPO passed the listing committee meeting and ranked fifth in the world as a superconducting magnet manufacturer in 2024
The Zhitong Finance App learned that on October 21, Ningbo Jianxin Superconductivity Technology Co., Ltd. (abbreviation: Jianxin Superconductivity) passed the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee meeting. GF Securities is its sponsor and plans to raise 865 million yuan. According to Insight Consulting data, in terms of installed capacity statistics, Jianxin Superconductivity ranked fifth among global superconducting magnet manufacturers in 2024, with a global market share of about 4.2%.
According to the prospectus, Jianxin Superconductivity is mainly engaged in R&D, production and sales of core components for medical magnetic resonance imaging (MRI) equipment. The main products include superconducting magnets, permanent magnets, and gradient coils.
In the field of superconductivity, the company has formed a rich product matrix including 1.5T zero-volatilization superconducting magnets, 1.5T liquid-free helium superconducting magnets, 3.0T zero-volatilization superconducting magnets, and open zero-volatilization superconducting magnets, and has become the number one independent supplier of superconducting magnets in the global magnetic resonance industry.
In the field of permanent magnets, the company can provide customers with a rich product range of high-quality permanent magnets through high-performance magnetic materials and high-efficiency magnetic circuit design, and introduce design techniques such as low eddy current and high openness. Currently, it is the world's largest supplier of permanent magnets for MRI equipment.
As the world's leading supplier of professional magnetic resonance core components, Jianxin Superconductor has established close cooperative relationships with well-known domestic and foreign MRI equipment manufacturers such as Japan's Fujifilm Group, American GE Healthcare, Italy's Baisheng Medical, Wandong Medical, Shenzhen Anke, Lianying Medical, Fuqing Medical, etc., and has promoted innovation in the overseas supply chain model of MRI equipment through overseas subsidiary layout and liquid helium maintenance patented technology development during transportation, greatly reducing the final delivery cost. More than 50% of the MRI equipment corresponding to the company's products was eventually sold to Japan, Europe, America and other overseas emerging market regions, promoting the global spread of MRI equipment.
The capital raised by the company will invest in a project with an annual output of 600 sets of liquid-free helium superconducting magnets, a technical improvement project with an annual output of 600 sets of high-field strength medical superconducting magnets, and a new superconducting magnet research and development project. The capital raised by the company revolves around the company's main business, focusing on national strategies and major needs, further increasing investment in R&D and innovation, further improving the industrial chain and product structure, and enhancing the competitiveness of the company's products and technology.
On the financial side, in 2022, 2023, 2024, and January-June 2025, the company's main business revenue was 332 million yuan, 422 million yuan, 401 million yuan and 238 million yuan, respectively. In 2024, the company's main business revenue declined slightly compared to 2023. On the one hand, revenue from permanent magnet products declined due to falling prices of magnetic steel raw materials, and on the other hand, due to the overall pressure on the domestic medical procurement market and the pace of implementation of medical equipment renewal policies.
